MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Invests $127,000 in Zoetis Inc. (NYSE:ZTS)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH purchased a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 651 shares of the company’s stock, valued at approximately $127,000.

Several other large investors have also recently added to or reduced their stakes in ZTS. SageView Advisory Group LLC grew its position in shares of Zoetis by 9.1% during the 4th quarter. SageView Advisory Group LLC now owns 5,553 shares of the company’s stock valued at $1,063,000 after buying an additional 464 shares during the last quarter. ICA Group Wealth Management LLC bought a new position in shares of Zoetis during the fourth quarter valued at approximately $118,000. MONECO Advisors LLC acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $201,000. HighPoint Advisor Group LLC bought a new stake in shares of Zoetis in the 4th quarter worth approximately $1,922,000. Finally, Nomura Holdings Inc. acquired a new position in Zoetis during the 4th quarter valued at approximately $1,825,000. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler boosted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday. Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $221.44.

Zoetis Trading Up 1.4 %

Shares of Zoetis stock opened at $192.65 on Tuesday. The business has a fifty day simple moving average of $188.43 and a 200-day simple moving average of $176.42. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The firm has a market cap of $87.91 billion, a price-to-earnings ratio of 37.12, a price-to-earnings-growth ratio of 2.95 and a beta of 0.89. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the company earned $1.41 EPS. Zoetis’s revenue was up 8.3% on a year-over-year basis. On average, equities analysts forecast that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Thursday, October 31st. Zoetis’s payout ratio is 33.14%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.